BRITAIN'S Medicines and Healthcare products Regulatory Agency (MHRA) has released a new five-year corporate plan which includes an outline of how it plans to deal with the uncertainty around the UK's exit from the EU.
MHRA says it plans to boost its use of real-world data to support regulatory decision making, with the 2018-2023 plan also highlighting ongoing technological and scientific challenges, including genomics and increased personalisation of products.
New areas of regulation are likely to include digital/AI-based products as well as novel supply chains.
Despite the looming impact of Brexit, MHRA notes that pharmaceuticals is a key sector where, in the interests of public health, an "ongoing active regulatory partnership with Europe" makes sense.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Apr 18
